nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-180-8-50-53nogr-1425Research ArticleКЛИНИЧЕСКАЯ ГАСТРОЭНТЕРОЛОГИЯCLINICAL GASTROENTEROLOGYКлеточно-молекулярные механизмы фиброза печени: роль микро-РНК-122 при хронических вирусных гепатитахCellular-molecular mechanisms of liver fibrosis: the role of micro-RNA-122 in chronic viral hepatitisПарпибоеваД. А.ParpiboevaD. A.

Парпибоева Динора Аюповна - Phd, доцент кафедры пропедевтики внутренних болезней № 2.

Ташкент

Dinora A. Parpiboeva - Cand. of Med. Sci., associate Professor of the Department of propedeutics of internal diseases № 2.

Tashkent

parpibaevadinora@gmail.comШукуроваФ. Н.ShukurovaF. N.

Шукурова Фазилат Нармаматовна - ассистент кафедры пропедевтики внутренних болезней № 2.

Ташкент

Fazilat N. Shukurova - assistant of the Department of propaedeutics of internal diseases № 2.

Tashkent

КаримовМ. Ш.KarimovM. Sh.

Каримов Мариф Шакирович - доктор медицинских наук, профессор, заведующий кафедрой пропедевтики внутренних болезней № 2.

Ташкент

Marif Sh. Karimov - doctor of medical Sciences, Professor, head of the Department of propaedeutics of internal diseases № 2.

Tashkent

Ташкентская медицинская академияУзбекистанTashkent medical AcademyUzbekistan202018102020085053Copyright © Парпибоева Д.А., Шукурова Ф.Н., Каримов М.Ш., 20202020Парпибоева Д.А., Шукурова Ф.Н., Каримов М.Ш.Parpiboeva D.A., Shukurova F.N., Karimov M.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/1425

В данной статье предоставлена вся информация на сегодняшний день о роли микро-РНК в развитии фиброза печени и степени воспалительного процесса при хронических вирусных заболеваниях печени. Для написания статьи осуществлялся поиск информации с использованием баз данных Scopus, WebofScience, MedLine, PubMed, GoogleScholar. Циркулирующие микро-РНК-122 были оценены как потенциальные неинвазивные биомаркеры активации фиброза печени и прогноза у пациентов с хроническим вирусным гепатитом.

Микро-РНК являются потенциальными маркерами диагностики и мониторинга состояния печеночной ткани, включая процессы фиброза и канцерогенеза. Рассмотрена терапевтическая эффективность, преимущества применения УДХК на экспрессию микро-РНК-122.

This article provides all the information to date about the role of micro-RNA in the development of liver fibrosis and the degree of inflammation in chronic viral liver diseases. To write the article, information was searched using the databases Scopus, Web of Science, MedLine, PubMed, and Google Scholar. Circulating microRNA-122 were evaluated as potential non-invasive biomarkers of liver fibrosis activation and prognosis in patients with chronic viral hepatitis.

Micro-RNAs are potential markers for the diagnosis and monitoring of liver tissue, including the processes of fibrosis and carcinogenesis. The therapeutic effectiveness and advantages of using UDCA on microRNA-122 expression are considered.

хронический вирусный гепатитмикро-РНКурсодезоксихолевая кислота обзорchronic viral hepatitismicro-RNAursodeoxycholic acid reviewReferencesOlson J. C. Acute-on-chronic and decompensated chronic liver failure: definitions, epidemiology and prognostication. Crit Care Clin. 2016, Vol. 32, no. 3, pp. 301–309.Olson J. C. Acute-on-chronic and decompensated chronic liver failure: definitions, epidemiology and prognostication. Crit Care Clin. 2016, Vol. 32, no. 3, pp. 301–309.Pares A., Planas R., Torres M. et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, doubleblind, randomized and multicenter trial. J Hepatol. 1998, Vol. 28, no. 4, pp. 615–621.Pares A., Planas R., Torres M. et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, doubleblind, randomized and multicenter trial. J Hepatol. 1998, Vol. 28, no. 4, pp. 615–621.Sayiner M., Koenig A., Henry L., Younossi Z. M. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis. 2016, Vol. 20, no. 2, pp. 205–214.Sayiner M., Koenig A., Henry L., Younossi Z. M. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis. 2016, Vol. 20, no. 2, pp. 205–214.Rino Y, Yukawa N, Yamamoto N. Does herbal medicine reduce the risk of hepatocellular carcinoma?. World J Gastroenterol. 2015, Vol. 21, no. 37, pp. 10598–10603.Rino Y, Yukawa N, Yamamoto N. Does herbal medicine reduce the risk of hepatocellular carcinoma?. World J Gastroenterol. 2015, Vol. 21, no. 37, pp. 10598–10603.Tsubota A., Kumada H. Th erapeutic strategies for hepatitis C. Nihon Rinsho. 2004, Vol. 62, Suppl. 7 (Pt 1), pp. 441–447.Tsubota A., Kumada H. Th erapeutic strategies for hepatitis C. Nihon Rinsho. 2004, Vol. 62, Suppl. 7 (Pt 1), pp. 441–447.Trinchet J. C., Coste T., Lévy V. G. et al. Treatment of alcoholic hepatitis with silymarin. A double-blind com-parative study in 116 patients. Gastroenterol Clin Biol. 1989, Vol. 13, no. 2, pp. 120–124.Trinchet J. C., Coste T., Lévy V. G. et al. Treatment of alcoholic hepatitis with silymarin. A double-blind com-parative study in 116 patients. Gastroenterol Clin Biol. 1989, Vol. 13, no. 2, pp. 120–124.Otsuka M, Kishikawa T, Yoshikawa T, et al. MicroRNAs and liver disease. J Hum Genet. 2017, Jan, 62(1), pp.75–80. doi: 10.1038/jhg.2016.53.Otsuka M, Kishikawa T, Yoshikawa T, et al. MicroRNAs and liver disease. J Hum Genet. 2017, Jan, 62(1), pp.75–80. doi: 10.1038/jhg.2016.53.Tsai WC, Hsu PW, Lai TC, et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic me-tastasis of hepatocellular carcinoma. Hepatology. 2009 May;49(5):1571–82. doi: 10.1002/hep.22806.Tsai WC, Hsu PW, Lai TC, et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic me-tastasis of hepatocellular carcinoma. Hepatology. 2009 May;49(5):1571–82. doi: 10.1002/hep.22806.Castro RE, Ferreira DM, Zhang X, et al. Identifi cation of microRNAs during rat liver regeneration aft er partial hepatectomy and modulation by ursodeoxycholic acid. Am J Physiol Gas-trointest Liver Physiol. 2010 Oct; 299(4): G887–97. doi: 10.1152/ajpgi.00216.2010.Castro RE, Ferreira DM, Zhang X, et al. Identifi cation of microRNAs during rat liver regeneration aft er partial hepatectomy and modulation by ursodeoxycholic acid. Am J Physiol Gas-trointest Liver Physiol. 2010 Oct; 299(4): G887–97. doi: 10.1152/ajpgi.00216.2010.Sato T., Liu X., Nelson A., Nakanishi M., Kanaji N., Wang X., Kim M., Li Y., Sun J., Michalski J., Patil A., Basma H., Holz O., Magnussen H., Rennard S. I. Reduced miR-146a increases prostaglandin E2 in chronic ob-structive pulmonary disease fi broblasts. Am. J. Respir.Sato T., Liu X., Nelson A., Nakanishi M., Kanaji N., Wang X., Kim M., Li Y., Sun J., Michalski J., Patil A., Basma H., Holz O., Magnussen H., Rennard S. I. Reduced miR-146a increases prostaglandin E2 in chronic ob-structive pulmonary disease fi broblasts. Am. J. Respir.Crit. Care Med., 2010, vol. 182, no. 8, pp. 1020–1029. doi: 10.1164/rccm.201001–0055OCCrit. Care Med., 2010, vol. 182, no. 8, pp. 1020–1029. doi: 10.1164/rccm.201001–0055OCSakamoto T, Morishita A, Nomura T, et al. Identifi cation of microRNA profi les associated with refractory primary biliary cirrhosis. Mol Med Rep. 2016 0ct;14(4):3350–6. doi: 10.3892/mmr.2016.5606.Sakamoto T, Morishita A, Nomura T, et al. Identifi cation of microRNA profi les associated with refractory primary biliary cirrhosis. Mol Med Rep. 2016 0ct;14(4):3350–6. doi: 10.3892/mmr.2016.5606.

The authors declare that there are no conflicts of interest present.